Gyre Therapeutics, Inc. (GYRE)
GYRE Stock Price Chart
Explore Gyre Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze GYRE price movements and trends.
GYRE Company Profile
Discover essential business fundamentals and corporate details for Gyre Therapeutics, Inc. (GYRE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Apr 2006
Employees
579.00
Website
https://www.gyretx.comCEO
Han Ying
Description
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
GYRE Financial Timeline
Browse a chronological timeline of Gyre Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Nov 2025
EPS estimate is $0.05, while revenue estimate is $33.55M.
Earnings released on 11 Aug 2025
EPS came in at $0.02 falling short of the estimated $0.03 by -33.33%, while revenue for the quarter reached $26.77M , missing expectations by -21.95%.
Earnings released on 9 May 2025
EPS came in at $0.03 matching the estimated $0.03, while revenue for the quarter reached $22.06M , missing expectations by -23.14%.
Earnings released on 17 Mar 2025
EPS came in at $0.01 falling short of the estimated $0.04 by -75.00%, while revenue for the quarter reached $27.87M , beating expectations by +18.60%.
Earnings released on 13 Nov 2024
EPS came in at $0.02 , while revenue for the quarter reached $25.49M .
Earnings released on 13 Aug 2024
EPS came in at $0.01 , while revenue for the quarter reached $25.23M , missing expectations by -77.77%.
Earnings released on 9 May 2024
EPS came in at $0.04 , while revenue for the quarter reached $27.17M .
Earnings released on 26 Mar 2024
EPS came in at -$0.68 falling short of the estimated -$0.60 by -13.57%, while revenue for the quarter reached $29.98M .
Stock split effective on 31 Oct 2023
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 26 Oct 2023
EPS came in at -$1.05 falling short of the estimated -$0.75 by -40.00%, while revenue for the quarter reached $30.74M .
Earnings released on 14 Aug 2023
EPS came in at -$0.07 matching the estimated -$0.07, while revenue for the quarter reached $26.14M .
Earnings released on 15 May 2023
EPS came in at $0.14 surpassing the estimated -$1.05 by +113.47%, while revenue for the quarter reached $24.44M .
Earnings released on 30 Mar 2023
EPS came in at -$0.05 surpassing the estimated -$1.58 by +96.53%, while revenue for the quarter reached -$794.00K , missing expectations by -298.50%.
Dividend declared on 13 Jan 2023
A dividend of $0.24 per share was announced, adjusted to $3.60.
Earnings released on 14 Nov 2022
EPS came in at -$0.05 surpassing the estimated -$1.50 by +96.35%, while revenue for the quarter reached $29.17M .
Dividend declared on 21 Sept 2022
A dividend of $1.43 per share was announced, adjusted to $21.45.
Earnings released on 15 Aug 2022
EPS came in at $0.08 surpassing the estimated -$3.68 by +102.06%, while revenue for the quarter reached $23.33M .
Earnings released on 9 May 2022
EPS came in at $0.08 , while revenue for the quarter reached $794.00K .
Earnings released on 31 Mar 2022
EPS came in at -$0.65 surpassing the estimated -$6.85 by +90.55%, while revenue for the quarter reached $2.44M , beating expectations by +206.15%.
Earnings released on 12 Nov 2021
EPS came in at -$0.80 , while revenue for the quarter reached $2.30M .
Earnings released on 5 Aug 2021
EPS came in at -$0.64 , while revenue for the quarter reached $1.13M .
Earnings released on 6 May 2021
EPS came in at -$0.79 , while revenue for the quarter reached $1.47M .
Earnings released on 4 Mar 2021
EPS came in at -$0.85 , while revenue for the quarter reached $2.03M .
Earnings released on 5 Nov 2020
EPS came in at -$0.73 , while revenue for the quarter reached $893.00K .
GYRE Stock Performance
Access detailed GYRE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.